Organization
DermBiont
9 clinical trials
Clinical trial
Randomized Double-Blind Vehicle-Controlled Study of the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic KeratosisStatus: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
Open-Label Study of the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa NigraStatus: Active (not recruiting), Estimated PCD: 2024-07-25
Clinical trial
An Observer-Blinded, Randomized, Aqueous Gel Controlled Trial of the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Interdigital Tinea PedisStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Open-Label Adaptive Design Study to Explore the Safety and Efficacy of Multiple Treatment Regimens With the Akt Inhibitor SM-020 Gel in 1.0% and 0.1% Gel Formulations in Subjects With Seborrheic KeratosisStatus: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Randomized, Observer-Blinded, Vehicle-Controlled Study on the Safety and Efficacy of Twice Daily Application of Ruboxistaurin (DBI-102) Gel Vs.Vehicle Gel Vs. Hydroquinone Cream on Sun-Exposed and Sun-Protected Skin of AdultsStatus: Completed, Estimated PCD: 2023-03-07
Clinical trial
An Observer-Blinded, Randomized, Aqueous Gel-Controlled Trial of the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With OnychomycosisStatus: , Estimated PCD: 2023-11-30
Clinical trial
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic DermatitisStatus: Terminated, Estimated PCD: 2022-09-09
Clinical trial
Open-Label Study of the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers (Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Observer-Blinded, Placebo-Controlled Study on the Safety and Efficacy of Twice Daily Application of SM-030 Gel 0.64% Vs. SM-030 Gel 0.08% Vs. Placebo Gel in Adults With MelasmaStatus: Recruiting, Estimated PCD: 2025-01-01